<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201221</date><key>pmc.key</key><document><id>7588935</id><infon key="license">CC BY</infon><passage><infon key="alt-title">A Comparison of Online Medical Crowdfunding in Canada, the UK, and the US</infon><infon key="article-id_doi">10.1001/jamanetworkopen.2020.21684</infon><infon key="article-id_pmc">7588935</infon><infon key="article-id_pmid">33104206</infon><infon key="article-id_publisher-id">zoi200733</infon><infon key="elocation-id">e2021684</infon><infon key="issue">10</infon><infon key="license">This is an open access article distributed under the terms of the CC-BY License.</infon><infon key="name_0">surname:Saleh;given-names:Sameh N.</infon><infon key="name_1">surname:Ajufo;given-names:Ezimamaka</infon><infon key="name_2">surname:Lehmann;given-names:Christoph U.</infon><infon key="name_3">surname:Medford;given-names:Richard J.</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">2020</infon><offset>0</offset><text>A Comparison of Online Medical Crowdfunding in Canada, the UK, and the US</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>74</offset><text>Key Points</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>85</offset><text>Question</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>94</offset><text>Why do individuals from Canada, the UK, and the US turn to medical crowdfunding and what factors are associated with funding success?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>228</offset><text>Findings</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>237</offset><text>In this cross-sectional study of 3396 crowdfunding campaigns designed to raise monetary donations for medical expenses, female gender, Black race, and routine care were associated with a strong fundraising disadvantage. For campaigns primarily funding treatment, routine care was overwhelmingly represented in the US (77.9%), in contrast to Canada (21.9%) and the UK (26.6%), and crowdfunding primarily funding alternative therapies (16.0%) was more common for cancer (23.5%) vs noncancer (6.5%) diagnoses.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>744</offset><text>Meaning</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>752</offset><text>These findings suggest that there are important differences in the reasons for medical crowdfunding across the 3 countries included in this analysis and that there are racial and gender disparities in crowdfunding success.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>975</offset><text>This cross-sectional study examines medical crowdfunding campaigns in Canada, the UK, and the US and evaluates whether campaign types and demographic characteristics of the beneficiaries are associated with the amounts of money raised.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1211</offset><text>Importance</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1222</offset><text>Despite major differences in their health care systems, medical crowdfunding is increasingly used to finance personal health care costs in Canada, the UK, and the US. However, little is known about the campaigns designed to raise monetary donations for medical expenses, the individuals who turn to crowdfunding, and their fundraising intent.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1565</offset><text>Objective</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1575</offset><text>To examine the demographic characteristics of medical crowdfunding beneficiaries, campaign characteristics, and their association with funding success in Canada, the UK, and the US.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1757</offset><text>Design, Setting, and Participants</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1791</offset><text>This cross-sectional study extracted and manually reviewed data from GoFundMe campaigns discoverable between February 2018 and March 2019. All available campaigns on each country domain’s GoFundMe medical discovery webpage that benefitted a unique patient(s) were included from Canada, the UK, and the US. Data analysis was performed from March to December 2019.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2156</offset><text>Exposures</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2166</offset><text>Campaign and beneficiary characteristics.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2208</offset><text>Main Outcomes and Measures</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2235</offset><text>Log-transformed amount raised in US dollars.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2280</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2288</offset><text>This study examined 3396 campaigns including 1091 in Canada, 1082 in the UK, and 1223 in the US. Campaigns in the US (median [IQR], $38 204 [$31 200 to $52 123]) raised more funds than campaigns in Canada ($12 662 [$9377 to $19 251]) and the UK ($6285 [$4028 to $12 348]). In the overall cohort per campaign, Black individuals raised 11.5% less (95% CI, −19.0% to −3.2%; P = .006) than non-Black individuals, and male individuals raised 5.9% more (95% CI, 2.2% to 9.7%; P = .002) than female individuals. Female (39.4% of campaigns vs 50.8% of US population; difference, 11.3%; 95% CI, 8.6% to 14.1%; P &lt; .001) and Black (5.3% of campaigns vs 13.4% of US population; difference, 8.1%; 95% CI, 6.8% to 9.3%; P &lt; .001) beneficiaries were underrepresented among US campaigns. Campaigns primarily for routine treatment expenses were approximately 3 times more common in the US (77.9% [272 of 349 campaigns]) than in Canada (21.9% [55 of 251 campaigns]; difference, 56.0%; 95% CI, 49.3-62.7%; P &lt; .001) or the UK (26.6% [127 of 478 campaigns]; difference, 51.4%; 95% CI, 45.5%-57.3%; P &lt; .001). However, campaigns for routine care were less successful overall. Approved, inaccessible care and experimental care raised 35.7% (95% CI, 25.6% to 46.7%; P &lt; .001) and 20.9% (95% CI, 13.3% to 29.1%; P &lt; .001), respectively, more per campaign than routine care. Campaigns primarily for alternative treatment expenses (16.1% [174 of 1079 campaigns]) were nearly 4-fold more common for cancer (23.5% [144 of 614 campaigns]) vs noncancer (6.5% [30 of 465 campaigns]) diagnoses.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>3892</offset><text>Conclusions and Relevance</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>3918</offset><text>Important differences were observed in the reasons individuals turn to medical crowdfunding in the 3 countries examined that suggest racial and gender disparities in fundraising success. More work is needed to understand the underpinnings of these findings and their implications on health care provision in the countries examined.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>4250</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4263</offset><text>Crowdfunding, the online solicitation of public donations, has become an important form of financing to pay for accumulated personal health care debts. Approximately one-third of all crowdfunding campaigns seek public monetary donations intended to pay for health care-related costs. The growing importance of medical crowdfunding (MCF) is reflected by trends on GoFundMe, the largest social crowdfunding platform in the world. In 2011, medical causes raised $1.6 million on GoFundMe; in 2014, the amount had increased almost a hundredfold to $150 million and in 2016, more than $650 million.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4856</offset><text>The growing reliance of health care consumers from the US on MCF has been attributed to increasing health care costs and the lack of a publicly funded health care system. However, the popularity of MCF in developed countries with universal health care such as Canada and the UK cannot be similarly explained. To date, MCF has financed a range of therapies, including experimental and alternative therapies. However, inequity, barriers to access, invasion of privacy, fraud, and dangerous, unproven therapies have been associated with MCF, but are poorly understood. Despite its growth and the concerns surrounding crowdfunding, there is a paucity of empirical research on MCF, including research on sociodemographic characteristics of beneficiaries and the diagnoses and treatments championed.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5650</offset><text>The objective of this study was to evaluate 3 important areas of MCF: (1) the purpose for crowdfunding in terms of diagnoses and therapies funded, (2) the characteristics of beneficiaries and campaigns, and (3) the factors associated with funding success. We selected GoFundMe as an ideal environment to study. As of 2018, the platform reportedly controlled 90% of the social crowdfunding market in the US and 80% of the global market. We studied consecutive campaigns from the crowdsourcing platform in Canada, the UK, and the US, the 3 countries with the largest markets on this platform.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>6241</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6249</offset><text>Study Population</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6266</offset><text>We conducted a cross-sectional analysis of campaigns launched between February 2018 and March 2019 from the GoFundMe domains in Canada, the UK, and the US. The crowdsourcing platform offers 21 cause categories for users to select; using a web scraping tool (Beautiful Soup), we extracted campaigns from the medical category only. For each country’s domain, we accessed all 1000 available medical campaigns on the Discover page at 2 time points first in February 2019 and 30 days later in March 2019. Accounting for duplicates, our queries resulted in 1107 unique campaigns in Canada, 1117 in the UK, and 1232 in the US (Figure 1). We excluded 61 campaigns that were not fundraising for individuals (eg, raising funds for a general cause, research, or nonprofit organization). The University of Texas Southwestern Human Research Protection Program Policies, Procedures, and Guidance did not require institutional review board approval or informed patient consent as all data were publicly available. This study followed the relevant portions of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.</text></passage><passage><infon key="file">jamanetwopen-e2021684-g001.jpg</infon><infon key="id">zoi200733f1</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>7415</offset><text>Study Flow Diagram</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7434</offset><text>Study Variables</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7450</offset><text>For each campaign, we extracted the quantitative data displayed on the campaign webpage, including the monetary goal, amount raised to date, number of donors, location, length of the fundraising campaign, Facebook shares, and GoFundMe hearts (the equivalent of webpage likes). Data were complete except for Facebook shares, with 2.6% of campaigns missing values, for which we imputed a value of zero. We converted all funds to US dollars based on currency exchange rates on the day we first accessed the data (Canadian dollar conversion rate of 0.76 on March 1, 2019, and British pound conversion rate of 1.32 on March 2, 2019).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8079</offset><text>Using the text and media on each initial campaign post, a 2-person manual review of the campaigns labeled data on demographic characteristics (including age, gender, and race), diagnosis, type of treatment (routine, experimental [ie, not yet approved], approved but inaccessible [ie, unavailable in the patient’s location], alternative [ie, treatments used in lieu of standard care], and unspecified), funding intent of the campaign (primarily for treatment costs or not), patient location (residing outside of the campaign country or not), and status (alive or deceased). The eAppendix in the Supplement describes in greater detail the variable definitions used. Each individual reviewed 55% of the data with 10% overlap between the reviewers. Interrater reliability (κ) greater than 0.8 indicates almost perfect agreement. Concordance analysis showed the κ value exceeded 0.77 for all but 1 category (eTable 1 in the Supplement). Age, diagnosis, gender, and race all had nearly perfect concordance (κ &gt; 0.97). There was greater than 89.2% raw agreement in all categories, with most greater than 98% (eTable 1 in the Supplement). A blinded third reviewer adjudicated any discrepancies between the 2 reviewers.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9302</offset><text>Statistical Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9323</offset><text>We performed descriptive data analyses of all variables to evaluate trends and common characteristics of MCF in the 3 countries. Given the nongaussian populations, we used Kruskal-Wallis, χ2, and Fisher exact testing to detect statistical differences among the 3 groups. To test for representativeness, we compared the campaign demographics with respective national census data (2016 Canadian census, 2018 UK estimate, 2018 US estimate) using a z test for proportions.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9794</offset><text>We performed multivariable linear regressions for the full cohort and by country using funds raised as the prespecified primary outcome variable as in prior studies. Given the right skewness of the outcome variable, we log-transformed it for the regression analysis. We constructed a pairwise Pearson correlation matrix and calculated the variance inflation factor among all variables and excluded repetitive variables with high collinearity from the analysis (eg, GoFundMe hearts [likes] and campaign narrative character count because of high correlation with the number of donors and narrative word count, respectively). To avoid multicollinearity in categorical variables, we dropped the normative or largest category to serve as the reference category (eg, adult for age, cancer for diagnosis, and routine care for the treatment type). We evaluated the models using the R2 coefficient. Because the outcome variable was log-transformed, we calculated percentage differences (and their 95% CIs) for the independent variables from the regression coefficients using the formula 100 × (eβ − 1), where β is the corresponding regression coefficient and e is the natural logarithm (approximately 2.718). A categorical variable reflects the percentage difference in the dependent variable (ie, amount raised) as compared with the reference level. A continuous variable reflects the percentage difference in the dependent variable (ie, amount raised) with a 1-unit change in the independent variable.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11298</offset><text>The α level of significance was set a priori at .05, and all hypothesis testing was 2-sided. We did not adjust for multiple comparisons as this was an exploratory study and should be interpreted as hypothesis generating. Inferences may not be reproducible, and further dedicated studies are needed to confirm the results. Statistical analyses were performed using Python statistical software version 3.7.2 (Python Software Foundation) from March to December 2019.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>11766</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11774</offset><text>Beneficiary Demographic Characteristics and Diagnoses</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11828</offset><text>Of the 3396 campaigns, 1091 originated in Canada, 1082 in the UK, and 1223 in the US. Table 1 presents the campaign characteristics, stratified by country. Most campaign beneficiaries were male (1767 beneficiaries [52.0%]), adult (2583 beneficiaries [76.1%]), and non-Black (3255 beneficiaries [95.8%]). Cancer (1850 campaigns [54.5%]) was the most common diagnosis represented in fundraisers, followed by neurologic (521 campaigns [15.3%]), other (353 campaigns [10.4%]), and trauma (332 campaigns [9.8%]) diagnoses.</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>12346</offset><text>Baseline Characteristics Stratified by Country for Entire Cohort</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;29.3%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;16.38%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;12.07%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.52%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;18.11%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;8.62%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; colspan=&quot;1&quot;&gt;Characteristic&lt;/th&gt;&lt;th colspan=&quot;4&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;Campaigns, No. (%)&lt;/th&gt;&lt;th rowspan=&quot;2&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n1&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;All (N = 3396)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada (n = 1091)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UK (n = 1082)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;US (n = 1223)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age group&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Adult, &amp;gt;18 y&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2583 (76.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;803 (73.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;813 (75.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;967 (79.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.006&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Minor, 2-18 y&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;604 (17.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;213 (19.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;212 (19.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;179 (17.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.002&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Infant, &amp;lt;2 y&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;139 (4.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60 (5.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34 (3.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45 (4.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; &amp;gt;1 Age group&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n2&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70 (2.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15 (1.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23 (2.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32 (2.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.11&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gender&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Male&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1767 (52.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;553 (50.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;492 (45.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;722 (59.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Female&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1540 (45.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;521 (47.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;550 (50.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;469 (38.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Transgender&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (0.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (1.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; &amp;gt;1 Gender&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n2&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;75 (2.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 (1.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (2.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32 (2.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.20&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Race&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Black&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;141 (4.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21 (1.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55 (5.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65 (5.3)&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Not Black&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3255 (95.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1070 (98.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1026 (94.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1158 (94.7)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Beneficiary outside country&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n3&quot;&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;140 (4.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (2.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;105 (9.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (0.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Diagnosis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Acute illness&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;124 (3.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34 (3.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31 (2.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59 (4.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.02&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1850 (54.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;659 (60.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;532 (49.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;659 (53.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Cardiac&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;108 (3.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19 (1.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (3.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56 (4.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Neurologic&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;521 (15.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;158 (14.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;218 (20.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;145 (11.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Transplant&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;108 (3.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45 (4.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 (1.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;46 (3.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Trauma&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;332 (9.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;90 (8.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70 (6.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;172 (14.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Other&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;353 (10.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;86 (7.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;181 (16.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;86 (7.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fundraising&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Goal, median (IQR), US $&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n4&quot;&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 000 (11 400-57 000)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19 000 (10 260-38 000)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13 200 (5534-33 396)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50 000 (35 000-100 000)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Raised, median (IQR), US $&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n4&quot;&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18 505 (8570-36 052)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 662 (9377-19 251)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6285 (4028-12 348)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38 204 (31 200-52 123)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Met goal&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1133 (33.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;415 (38.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;333 (30.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;385 (31.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Donors, median (IQR), No.&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;190 (106-332)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;153 (104-232)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;110 (68-194)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;321 (222-498)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Primarily funding treatment&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t1n5&quot;&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1079 (31.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;251 (23.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;478 (44.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;349 (28.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaign information, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Facebook shares, No.&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;632 (306-1100)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;565 (316-926)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;386 (174-808)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1000 (547-1700)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; GoFundMe hearts, No.&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;187 (104-331)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;155 (103-232)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;109 (67-191)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;322 (222-506)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Fundraising length, mo&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (1-6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (2-8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (1-8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (1-4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Narrative&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Words&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;317 (193-512)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;321 (201-509)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;343 (193-566)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;301 (188-478)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Characters&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1844 (1118-2.978)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1884 (1172-2983)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1942 (1090-3256)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1762 (1091-2819)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.02&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>12411</offset><text>Characteristic	Campaigns, No. (%)	P valuea	 	All (N = 3396)	Canada (n = 1091)	UK (n = 1082)	US (n = 1223)	 	Age group						 	 Adult, &gt;18 y	2583 (76.1)	803 (73.6)	813 (75.1)	967 (79.1)	.006	 	 Minor, 2-18 y	604 (17.8)	213 (19.5)	212 (19.6)	179 (17.8)	.002	 	 Infant, &lt;2 y	139 (4.1)	60 (5.5)	34 (3.1)	45 (4.1)	.01	 	 &gt;1 Age groupb	70 (2.1)	15 (1.4)	23 (2.1)	32 (2.6)	.11	 	Gender						 	 Male	1767 (52.0)	553 (50.7)	492 (45.5)	722 (59.0)	&lt;.001	 	 Female	1540 (45.3)	521 (47.8)	550 (50.8)	469 (38.4)	&lt;.001	 	 Transgender	14 (0.4)	0	14 (1.3)	0	&lt;.001	 	 &gt;1 Genderb	75 (2.2)	17 (1.6)	26 (2.4)	32 (2.6)	.20	 	Race						 	 Black	141 (4.2)	21 (1.9)	55 (5.1)	65 (5.3)	&lt;.001	 	 Not Black	3255 (95.8)	1070 (98.1)	1026 (94.9)	1158 (94.7)	 	Beneficiary outside countryc	140 (4.1)	30 (2.7)	105 (9.7)	6 (0.5)	&lt;.001	 	Diagnosis						 	 Acute illness	124 (3.7)	34 (3.1)	31 (2.9)	59 (4.8)	.02	 	 Cancer	1850 (54.5)	659 (60.4)	532 (49.2)	659 (53.9)	&lt;.001	 	 Cardiac	108 (3.2)	19 (1.7)	33 (3.0)	56 (4.6)	&lt;.001	 	 Neurologic	521 (15.3)	158 (14.5)	218 (20.1)	145 (11.9)	&lt;.001	 	 Transplant	108 (3.2)	45 (4.1)	17 (1.6)	46 (3.8)	.001	 	 Trauma	332 (9.8)	90 (8.2)	70 (6.5)	172 (14.1)	&lt;.001	 	 Other	353 (10.4)	86 (7.9)	181 (16.7)	86 (7.0)	&lt;.001	 	Fundraising						 	 Goal, median (IQR), US $d	30 000 (11 400-57 000)	19 000 (10 260-38 000)	13 200 (5534-33 396)	50 000 (35 000-100 000)	&lt;.001	 	 Raised, median (IQR), US $d	18 505 (8570-36 052)	12 662 (9377-19 251)	6285 (4028-12 348)	38 204 (31 200-52 123)	&lt;.001	 	 Met goal	1133 (33.4)	415 (38.0)	333 (30.7)	385 (31.4)	&lt;.001	 	 Donors, median (IQR), No.	190 (106-332)	153 (104-232)	110 (68-194)	321 (222-498)	&lt;.001	 	 Primarily funding treatmente	1079 (31.8)	251 (23.0)	478 (44.2)	349 (28.5)	&lt;.001	 	Campaign information, median (IQR)						 	 Facebook shares, No.	632 (306-1100)	565 (316-926)	386 (174-808)	1000 (547-1700)	&lt;.001	 	 GoFundMe hearts, No.	187 (104-331)	155 (103-232)	109 (67-191)	322 (222-506)	&lt;.001	 	 Fundraising length, mo	4 (1-6)	5 (2-8)	5 (1-8)	3 (1-4)	&lt;.001	 	 Narrative						 	 Words	317 (193-512)	321 (201-509)	343 (193-566)	301 (188-478)	.003	 	 Characters	1844 (1118-2.978)	1884 (1172-2983)	1942 (1090-3256)	1762 (1091-2819)	.02	 	</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>14644</offset><text>Abbreviation: IQR, interquartile range.</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14684</offset><text>Given the nongaussian populations, we used Kruskal-Wallis, χ2, and Fischer exact testing to detect statistical differences among the 3 groups.</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14829</offset><text>More than 1 beneficiary was included in the same campaign so no singular age and/or gender could be identified.</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14941</offset><text>Beneficiary lives in a different country than the campaigning country (eg, Canadian campaign raising funds for family member in the Philippines).</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>15087</offset><text>All monetary values were converted to US dollars based on currency exchange rates at the time the data was accessed (March 1, 2019, for Canadian dollar; and March 2, 2019, for British pound).</text></passage><passage><infon key="file">zoi200733t1.xml</infon><infon key="id">zoi200733t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>15279</offset><text>Campaign clearly identifies that its primary funding goal is for medical treatment. See eAppendix in the Supplement for details.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15408</offset><text>Table 2 compares the campaign demographic characteristics in each country to its national census. The US had the highest proportion (59.0%) of male beneficiaries (Canada vs US and UK vs US, both P &lt; .001). Female individuals comprise 50.8% of the US population, but were beneficiaries in only 39.4% of US campaigns (difference, 11.3%; 95% CI, 8.6%-14.1%; P &lt; .001). In the US, adults were overrepresented compared with the census (81.2% vs 77.6%; difference, 3.6%; 95% CI, 1.4%-5.8%; P = .003). The US had more Black beneficiaries than Canada and a similar proportion to the UK. However, compared with national census representations, Black beneficiaries were most underrepresented in the US (5.3% vs 13.4%; difference, 8.1%; 95% CI, 6.8%-9.3%; P &lt; .001). Black Canadians were also underrepresented (1.9% vs 3.5%; difference, 1.6%; 95% CI, 0.7%-2.4%; P = .004), and Blacks in the UK were overrepresented in campaigns (5.1% vs 3.3%; difference, 1.8%; 95% CI, 0.7%-3.3%; P &lt; .001).</text></passage><passage><infon key="file">zoi200733t2.xml</infon><infon key="id">zoi200733t2</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>16412</offset><text>Comparison of the Proportion of Campaign Representation to the Proportion of Population According to National Census Data (2016 Canada, 2018 UK, 2018 US)a</text></passage><passage><infon key="file">zoi200733t2.xml</infon><infon key="id">zoi200733t2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;16.39%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;12.07%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;9.48%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;8.62%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;12.93%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;6.89%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;6.89%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;11.21%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;7.76%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;7.76%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; colspan=&quot;1&quot;&gt;Characteristics&lt;/th&gt;&lt;th colspan=&quot;3&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;Canada&lt;/th&gt;&lt;th colspan=&quot;3&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;UK&lt;/th&gt;&lt;th colspan=&quot;3&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;US&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;Campaigns, No. (%)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Census, %&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t2n2&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaigns, No. (%)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Census, %&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t2n2&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaigns, No. (%)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Census, %&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t2n2&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age group&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Adult, &amp;gt;18 y&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;803 (74.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;80.0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;813 (76.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78.8&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;967 (81.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;77.6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Minor, 2-18 y&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;213 (19.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17.9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.11&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;212 (20.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18.9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.34&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;179 (15.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20.1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Infant, &amp;lt;2 y&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60 (5.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34 (3.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.03&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45 (3.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gender&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Male&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;553 (51.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49.1&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;.12&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;492 (47.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49.3&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;.18&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;722 (60.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49.2&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Female&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;521 (48.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50.9&lt;/td&gt;&lt;td valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; rowspan=&quot;1&quot;&gt;550 (52.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50.7&lt;/td&gt;&lt;td valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; rowspan=&quot;1&quot;&gt;469 (39.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Race&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Black&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21 (1.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;.005&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55 (5.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.1&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65 (5.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13.4&lt;/td&gt;&lt;td rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Not Black&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1070 (98.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;96.5&lt;/td&gt;&lt;td valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; rowspan=&quot;1&quot;&gt;1026 (94.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;96.9&lt;/td&gt;&lt;td valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; rowspan=&quot;1&quot;&gt;1158 (94.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;86.6&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>16567</offset><text>Characteristics	Canada	UK	US	 	Campaigns, No. (%)	Census, %	P valueb	Campaigns, No. (%)	Census, %	P valueb	Campaigns, No. (%)	Census, %	P valueb	 	Age group										 	 Adult, &gt;18 y	803 (74.8)	80.0	&lt;.001	813 (76.8)	78.8	.10	967 (81.2)	77.6	.003	 	 Minor, 2-18 y	213 (19.8)	17.9	.11	212 (20.0)	18.9	.34	179 (15.0)	20.1	&lt;.001	 	 Infant, &lt;2 y	60 (5.6)	2.1	&lt;.001	34 (3.2)	2.3	.03	45 (3.8)	2.4	.001	 	Gender										 	 Male	553 (51.5)	49.1	.12	492 (47.2)	49.3	.18	722 (60.6)	49.2	&lt;.001	 	 Female	521 (48.5)	50.9	550 (52.8)	50.7	469 (39.4)	50.8	 	Race										 	 Black	21 (1.9)	3.5	.005	55 (5.1)	3.1	&lt;.001	65 (5.3)	13.4	&lt;.001	 	 Not Black	1070 (98.1)	96.5	1026 (94.9)	96.9	1158 (94.7)	86.6	 	</text></passage><passage><infon key="file">zoi200733t2.xml</infon><infon key="id">zoi200733t2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17256</offset><text>Campaigns with more than one beneficiary were excluded.</text></passage><passage><infon key="file">zoi200733t2.xml</infon><infon key="id">zoi200733t2</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>17312</offset><text>The P value is determined by using the z test to compare the proportion of campaign representation with the proportion of the national census in each country.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17471</offset><text>Fundraising Characteristics</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17499</offset><text>Campaigns in this study collectively raised $92.9 million, accounting for 51.9% of the total funds sought. US campaigns (median [IQR], $38 204 [$31 200 to $52 123]) raised more funds than campaigns in Canada ($12 662 [$9377 to $19 251]) and the UK ($6285 [$4028 to $12 348]). Only 33.3% of all campaigns had met their goal at data extraction. Funds raised ranged from $2772 to $343 762 per campaign. US campaigns set higher fundraising goals than those in Canada and the UK (Table 1). Accounting for $57.8 million (62.2% of the total funds raised), US campaigns raised approximately 3 times the funds of Canadian campaigns and 6 times the funds of UK campaigns on average, despite being 2 months shorter in duration. US campaigns had significantly more donors and Facebook shares compared with campaigns in Canada and the UK.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>18327</offset><text>Treatment Type</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18342</offset><text>Figure 2 summarizes the treatment types for which campaigns raised funding, stratified by country. Although routine care was the most common treatment type, accounting for 69.4% of all campaigns, 83.9% of US campaigns focused on routine care compared with 68.5% of Canadian campaigns (difference, 15.4%; 95% CI, 12.0%-18.9%; P &lt; .001) and 54.0% of UK campaigns (difference, 29.9%; 95% CI, 26.3%-33.5%; P &lt; .001) (Figure 2A). Experimental, approved but inaccessible, and alternative care were all more common among Canadian and UK campaigns compared with US campaigns. The UK had substantially more approved but inaccessible care than Canada (14.1% vs 6.0%; difference, 8.1%; 95% CI, 5.6%-10.6%; P &lt; .001) or the US (14.1% vs 0.3%; difference, 13.8%; 95% CI, 11.6%-15.8%; P &lt; .001). Approximately one-third of all campaigns (1078 campaigns) were fundraising primarily for treatment expenses. Of these, campaigns funding routine care were approximately 3 times more common in the US (77.9% [272 of 349 campaigns]) than in Canada (21.9% [55 of 251 campaigns]; difference, 56.0%; 95% CI, 49.3-62.7%; P &lt; .001) or the UK (26.6% [127 of 478 campaigns]; difference, 51.4%; 95% CI, 45.5%-57.3%; P &lt; .001) (Figure 2B). Campaigns primarily for treatment expenses in Canada and the UK were similarly distributed among routine, alternative, experimental, and unavailable therapies. Combined, fundraising for experimental and approved but inaccessible therapies was the purpose of approximately 50% of campaigns both in Canada and in the UK. Campaigns primarily for alternative treatment expenses (16.1% [174 of 1079 campaigns]) were nearly 4-fold more common for cancer (23.5% [144 of 614 campaigns]) vs noncancer (6.5% [30 of 465 campaigns]) diagnoses (eTable 2 in the Supplement).</text></passage><passage><infon key="file">jamanetwopen-e2021684-g002.jpg</infon><infon key="id">zoi200733f2</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>20137</offset><text>Primary Type of Treatment by Country </text></passage><passage><infon key="file">jamanetwopen-e2021684-g002.jpg</infon><infon key="id">zoi200733f2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>20175</offset><text>Graphs show type of treatment for all campaigns (A) and for campaigns primarily for treatment costs (B). χ2 testing was used to derive P values comparing each type of treatment in the 3 countries.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20374</offset><text>Associations With Campaign Success</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20409</offset><text>Findings from multivariable regression analysis of the log-transformed funds raised per campaign are presented in Table 3. Campaign country was most strongly associated with the amount raised in the full cohort. Campaigns from Canada and the UK yielded 59.1% (95% CI, −61.0% to −57.1%; P &lt; .001) and 78.4% (95% CI, −79.4% to −77.3%; P &lt; .001) less funding than US campaigns, respectively. Number of donors and fundraising goals were strongly associated with funding success (Table 3). Facebook shares were weakly associated with funding success in the main regression model, but when donor numbers (moderately collinear with Facebook shares) were removed from the model, Facebook shares became strongly associated with funds raised (data not shown).</text></passage><passage><infon key="file">zoi200733t3.xml</infon><infon key="id">zoi200733t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>21175</offset><text>Percentage Differences in Amount Raised for the Full Cohort and for Each Country</text></passage><passage><infon key="file">zoi200733t3.xml</infon><infon key="id">zoi200733t3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;17.18%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.58%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;4.92%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;13.94%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;4.92%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;16.4%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;4.92%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;17.22%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;4.92%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; colspan=&quot;1&quot;&gt;Characteristics&lt;/th&gt;&lt;th colspan=&quot;8&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;Differences, % (95% CI)&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t3n1&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; colspan=&quot;1&quot; align=&quot;left&quot; scope=&quot;colgroup&quot; rowspan=&quot;1&quot;&gt;All (&lt;italic&gt;R&lt;/italic&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.72)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada (&lt;italic&gt;R&lt;/italic&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.41)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UK (&lt;italic&gt;R&lt;/italic&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.52)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;US (&lt;italic&gt;R&lt;/italic&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.47)&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Demographic characteristics and location&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Gender&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Female&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Male&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.9 (2.2 to 9.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.002&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.9 (5.4 to 16.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.2 (−3.0 to 14.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.22&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.5 (1.0 to 8.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.01&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Transgender&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−26.7 (−44.2 to −3.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.03&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−19.9 (−43.8 to 14.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.22&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Age&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Adult&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Minor&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−5.4 (−9.7 to −0.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.02&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−5.5 (−11.6 to 1.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−6.3 (−15.2 to 3.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.20&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−1.9 (−6.5 to 3.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.82&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Infant&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−12.5 (−20.0 to −4.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.003&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−8.6 (−18.4 to 2.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.12&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−21.1 (−37.1 to −0.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.04&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−1.0 (−9.6 to 8.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.45&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Black race&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−11.5 (−19.0 to −3.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.006&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−15.8 (−30.0 to 1.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.07&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−10.3 (−25.8 to 8.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.26&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−3.7 (−10.7 to 3.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.33&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Country domain&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; US&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Canada&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−59.1 (−61.0 to −57.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; UK&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−78.4 (−79.4 to −77.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-Medicaid expansion&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.4 (−2.4 to 5.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.48&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Beneficiary outside country&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t3n2&quot;&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;bold&gt;−&lt;/bold&gt;0.2 (−9.3 to 9.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.96&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−2.6 (−17.3 to 14.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.75&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.8 (−10.7 to 22.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.57&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−8.5 (−28.2 to 16.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.47&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Beneficiary deceased&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−6.0 (−16.1 to 5.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.29&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5 (−15.6 to 26.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.74&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−13.9 (−34.0 to 12.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.27&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−7.3 (−15.8 to 2.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Diagnosis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Cancer&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Acute illness&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−9.2 (−17.0 to −0.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.03&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−14.4 (−25.7 to −1.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.03&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−7.0 (−25.5 to 16.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.52&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−7.5 (−14.4 to −0.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Cardiac&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−0.6 (−9.4 to 9.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.90&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−5.1 (−21.6 to 14.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.59&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−6.5 (−25.8 to 17.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.57&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.4 (−4.8 to 10.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.52&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Neurologic&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0 (−4.7 to 5.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.99&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−4.3 (−11.2 to 3.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.24&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.5 (−3.6 to 17.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.22&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.2 (−0.1 to 10.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.05&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Transplant&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−12.2 (−19.9 to −3.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.005&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−17.5 (−26.8 to −7.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.002&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−5.2 (−28.8 to 26.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.72&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−4.8 (−12.3 to 3.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.24&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Trauma&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−6.6 (−12.1 to −0.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.029&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−0.1 (−9.2 to 9.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.98&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−6.1 (−20.0 to 10.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.44&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−1.7 (−6.7 to 3.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.50&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Treatment type and details&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Routine care&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 [Reference]&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Alternative&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.5 (−0.7 to 14.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.08&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7.2 (−3.4 to 18.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.19&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7.9 (−7.4 to 25.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.33&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.9 (−6.3 to 8.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.81&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Approved (not accessible)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35.7 (25.6 to 46.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.8 (11.6 to 41.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24.4 (8.7 to 42.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70.6 (27.0 to 129.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Experimental (not approved)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20.9 (13.3 to 29.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.1 (−4.6 to 15.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.31&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21.5 (5.1 to 40.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.008&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.4 (3.6 to 11.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.004&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Campaign information and social media&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Goal, in $10 000 US&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t3n3&quot;&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.7 (0.6 to 0.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.8 (2.1 to 3.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.5 (0.9 to 2.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.4 (0.3 to 0.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Fundraising length, mo&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.2 (0.6 to 1.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.5 (1.6 to 3.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.8 (1.6 to 4.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.2 (2.1 to 4.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Primarily funding treatment&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;zoi200733t3n4&quot;&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.5 (−4.1 to 5.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.85&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−1.3 (−9.0 to 7.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.75&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.1 (−10 to 13.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.85&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;−6.6 (−10.2 to −2.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Narrative, in 100s of words&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.8 (0.3 to 1.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.003&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.9 (0.2 to 1.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.02&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.7 (0.6 to 2.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.003&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1 (−0.4 to 0.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.79&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Donors, in 100s&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.5 (7.9 to 9.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.7 (7.3 to 10.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.1 (6.3 to 10.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.8 (4.3 to 5.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt; Facebook shares, in 100s&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.3 (0.1 to 0.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.4 (−0.1 to 0.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.16&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.4 (0.8 to 2.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.1 (−0.1 to 0.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;.27&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>21256</offset><text>Characteristics	Differences, % (95% CI)a	 	All (R2 = 0.72)	P value	Canada (R2 = 0.41)	P value	UK (R2 = 0.52)	P value	US (R2 = 0.47)	P value	 	Demographic characteristics and location									 	 Gender									 	 Female	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	 	 Male	5.9 (2.2 to 9.7)	.002	10.9 (5.4 to 16.7)	&lt;.001	5.2 (−3.0 to 14.1)	.22	4.5 (1.0 to 8.2)	.01	 	 Transgender	−26.7 (−44.2 to −3.7)	.03	NA	NA	−19.9 (−43.8 to 14.2)	.22	NA	NA	 	 Age									 	 Adult	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	 	 Minor	−5.4 (−9.7 to −0.9)	.02	−5.5 (−11.6 to 1.0)	.10	−6.3 (−15.2 to 3.6)	.20	−1.9 (−6.5 to 3.0)	.82	 	 Infant	−12.5 (−20.0 to −4.4)	.003	−8.6 (−18.4 to 2.4)	.12	−21.1 (−37.1 to −0.8)	.04	−1.0 (−9.6 to 8.3)	.45	 	 Black race	−11.5 (−19.0 to −3.2)	.006	−15.8 (−30.0 to 1.2)	.07	−10.3 (−25.8 to 8.4)	.26	−3.7 (−10.7 to 3.9)	.33	 	Country domain									 	 US	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	 	 Canada	−59.1 (−61.0 to −57.1)	&lt;.001	NA	NA	NA	NA	NA	NA	 	 UK	−78.4 (−79.4 to −77.3)	&lt;.001	NA	NA	NA	NA	NA	NA	 	Non-Medicaid expansion	NA	NA	NA	NA	NA	NA	1.4 (−2.4 to 5.4)	.48	 	Beneficiary outside countryb	−0.2 (−9.3 to 9.7)	.96	−2.6 (−17.3 to 14.7)	.75	4.8 (−10.7 to 22.9)	.57	−8.5 (−28.2 to 16.5)	.47	 	Beneficiary deceased	−6.0 (−16.1 to 5.5)	.29	3.5 (−15.6 to 26.9)	.74	−13.9 (−34.0 to 12.3)	.27	−7.3 (−15.8 to 2.0)	.12	 	Diagnosis									 	 Cancer	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	0 [Reference]	NA	 	 Acute illness	−9.2 (−17.0 to −0.7)	.03	−14.4 (−25.7 to −1.4)	.03	−7.0 (−25.5 to 16.1)	.52	−7.5 (−14.4 to −0.1)	.05	 	 Cardiac	−0.6 (−9.4 to 9.1)	.90	−5.1 (−21.6 to 14.9)	.59	−6.5 (−25.8 to 17.9)	.57	2.4 (−4.8 to 10.1)	.52	 	 Neurologic	0.0 (−4.7 to 5.0)	.99	−4.3 (−11.2 to 3.0)	.24	6.5 (−3.6 to 17.7)	.22	5.2 (−0.1 to 10.7)	.05	 	 Transplant	−12.2 (−19.9 to −3.8)	.005	−17.5 (−26.8 to −7.0)	.002	−5.2 (−28.8 to 26.2)	.72	−4.8 (−12.3 to 3.4)	.24	 	 Trauma	−6.6 (−12.1 to −0.7)	.029	−0.1 (−9.2 to 9.9)	.98	−6.1 (−20.0 to 10.2)	.44	−1.7 (−6.7 to 3.5)	.50	 	Treatment type and details									 	 Routine care	0 [Reference]		0 [Reference]		0 [Reference]		0 [Reference]		 	 Alternative	6.5 (−0.7 to 14.3)	.08	7.2 (−3.4 to 18.9)	.19	7.9 (−7.4 to 25.8)	.33	0.9 (−6.3 to 8.6)	.81	 	 Approved (not accessible)	35.7 (25.6 to 46.7)	&lt;.001	25.8 (11.6 to 41.8)	&lt;.001	24.4 (8.7 to 42.3)	.001	70.6 (27.0 to 129.0)	&lt;.001	 	 Experimental (not approved)	20.9 (13.3 to 29.1)	&lt;.001	5.1 (−4.6 to 15.8)	.31	21.5 (5.1 to 40.4)	.008	11.4 (3.6 to 11.4)	.004	 	Campaign information and social media									 	 Goal, in $10 000 USc	0.7 (0.6 to 0.7)	&lt;.001	2.8 (2.1 to 3.5)	&lt;.001	1.5 (0.9 to 2.1)	&lt;.001	0.4 (0.3 to 0.5)	&lt;.001	 	 Fundraising length, mo	1.2 (0.6 to 1.8)	&lt;.001	2.5 (1.6 to 3.3)	&lt;.001	2.8 (1.6 to 4.0)	&lt;.001	3.2 (2.1 to 4.3)	&lt;.001	 	 Primarily funding treatmentd	0.5 (−4.1 to 5.3)	.85	−1.3 (−9.0 to 7.0)	.75	1.1 (−10 to 13.7)	.85	−6.6 (−10.2 to −2.9)	.001	 	 Narrative, in 100s of words	0.8 (0.3 to 1.3)	.003	0.9 (0.2 to 1.5)	.02	1.7 (0.6 to 2.9)	.003	0.1 (−0.4 to 0.6)	.79	 	 Donors, in 100s	8.5 (7.9 to 9.2)	&lt;.001	8.7 (7.3 to 10.2)	&lt;.001	8.1 (6.3 to 10.0)	&lt;.001	4.8 (4.3 to 5.3)	&lt;.001	 	 Facebook shares, in 100s	0.3 (0.1 to 0.5)	&lt;.001	0.4 (−0.1 to 0.8)	.16	1.4 (0.8 to 2.0)	&lt;.001	0.1 (−0.1 to 0.2)	.27	 	</text></passage><passage><infon key="file">zoi200733t3.xml</infon><infon key="id">zoi200733t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>24798</offset><text>Values (and their 95% CI) are derived from a multivariable linear regression using an outcome variable of log-transformed amount raised using the formula 100 × (eβ − 1), where β is the corresponding regression coefficient. For categorical variables, values reflect percentage difference in amount raised as compared with the reference level. For continuous variables, values reflect percentage difference in amount raised with a 1-unit change in the variable.</text></passage><passage><infon key="file">zoi200733t3.xml</infon><infon key="id">zoi200733t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>25267</offset><text>Beneficiary of the campaign lives in a different country than a campaigning country (eg, Canadian campaign raising funds for family member in the Philippines).</text></passage><passage><infon key="file">zoi200733t3.xml</infon><infon key="id">zoi200733t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>25427</offset><text>All monetary values were converted to US dollars based on currency exchange rates at the time the data was accessed. See Methods for details.</text></passage><passage><infon key="file">zoi200733t3.xml</infon><infon key="id">zoi200733t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>25569</offset><text>Campaign clearly identifies that its primary funding goal is for medical treatment. See eAppendix in the Supplement for details.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>25698</offset><text>The gender and race of beneficiaries were also associated with funding success. Overall, Black beneficiaries raised 11.5% less per campaign (95% CI, −19.0% to −3.2%; P = .006) with concordant but nonsignificant trend in the country-specific analyses. Overall, male beneficiaries raised 5.9% more per campaign than their female counterparts (95% CI, 2.2% to 9.7%; P = .002); this trend was most pronounced in Canadian campaigns with male individuals raising 10.9% more than female individuals (P &lt; .001). Campaigns for approved but inaccessible care and experimental care raised 35.7% (95% CI, 25.6% to 46.7%; P &lt; .001) and 20.9% (95% CI, 13.3% to 29.1%; P &lt; .001) more than campaigns for routine care, respectively. The association was strongest in the US where campaigns for approved but inaccessible care received 70.6% (95% CI, 27.0% to 129.0%; P &lt; .001) more per campaign than those for routine care.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>26631</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26642</offset><text>We examined 3396 medical campaigns from Canada, the UK, and the US, the 3 largest crowdfunding markets on GoFundMe, to characterize MCF beneficiaries, reasons for MCF, and factors associated with funding success. To our knowledge, this is the largest quantitative analysis of the MCF landscape to date. US campaigns set higher goals and raised more funds than campaigns from Canada or the UK. However, approximately two-thirds of campaigns in each country did not meet their funding goals. In the US, nearly 80% of campaigns primarily funding treatment were for routine care, whereas in Canada and the UK, funding for routine care was sought about as frequently as funding for alternative, approved but inaccessible, and experimental therapies. Campaigns for routine care were negatively associated with crowdfunding success, whereas campaigns for experimental and approved but inaccessible therapies were positively associated with funding success. Finally, we observed significant gender and racial inequities among beneficiaries.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>27675</offset><text>Beneficiary Demographic Characteristics and Inequities in Crowdfunding</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27746</offset><text>Crowdfunding was initially heralded as a digital safety net or a mechanism for democratizing charity where anyone could benefit. However, anecdotal and empirical evidence suggests that crowdfunding may exacerbate socioeconomic inequities. In our study, Black and female individuals were underrepresented in US campaigns and Black individuals were underrepresented in Canadian campaigns. In another study of 637 randomly sampled US MCF campaigns from GoFundMe, non-White beneficiaries were also significantly underrepresented, constituting only 19% of the sample although this group represents 27% of the US population. Within our sample, female and Black beneficiaries raised 5.9% and 11.5% less than their male and non-Black counterparts, respectively. Similarly, in a US study of 850 campaigns for organ transplantation, female individuals raised 27% less than male individuals. In a Canadian study of 319 campaigns, being a visible ethnic minority was associated with raising 15% less in funds, before adjustment for technological competency (using quantity of campaign images, videos, updates, and perks) and 6% less after adjustment.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28885</offset><text>Race and gender disparities reflect the pillars on which MCF is dependent: access to technology, literacy, social capital, and perception. Those with socioeconomic disadvantage are more likely to experience a digital divide that limits online participation because of a lack of access to information technology (eg, computer and internet). Writing, media, and health care literacies, which reflect socioeconomic privilege, enable an individual to augment his or her illness narrative, communicate deservingness, and thereby, generate campaign appeal and influence. Furthermore, broader, more affluent social communities and larger social media networks are well-recognized factors associated with crowdfunding success. Finally, conscious and unconscious systemic racial and gender biases likely obscure perception of worthiness in MCF campaigns. Our findings suggest that MCF facilitates the distribution of resources according to biases and preferences and thus, contribute to widening social inequities.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>29891</offset><text>Reasons Individuals Turn to Medical Crowdfunding and Clues to Possible Gaps in Health Care Funding</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29990</offset><text>If trends in MCF reflect health care costs and gaps in insurance coverage, our findings may point to possible country-specific shortcomings in health care funding. The trends seen in the US suggest that its greatest systemic funding failure may lie in the provision of routine health care. Despite a decrease in the uninsured rate after passage of The Affordable Care Act, as of 2018, 11.1% of adults younger than 65 years were uninsured and 29% were estimated to be underinsured (ie, out-of-pocket costs or deductibles comprising 5% to 10% of their income). For US campaigns across all diagnoses, and especially for common diagnoses such as acute illness and trauma, routine care was the most common reason for fundraising. Among campaigns primarily funding treatments, 77.9% were for routine care in the US compared with 21.9% and 26.6% of analogous campaigns in Canada and the UK, respectively. Interestingly, campaigns for routine care raised substantially less in the US, perhaps reflecting the saturation of the US MCF market with this type of campaign. US health care costs are the highest in the developed world, and health insurance deductibles have increased 8 times as much as wages since 2008. The disproportionate popularity of MCF in the US, combined with the predominance of campaigns for routine care, likely reflect high out-of-pocket costs associated with essential health care in the US.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31397</offset><text>The trends seen in Canada and the UK may reflect unique failures within their publicly funded health care systems. Routine care comprised 21.9% and 26.6% of campaigns primarily funding treatment in Canada and the UK, respectively, pointing to possible gaps despite universal health care. These gaps may be associated with rising out-of-pocket medication costs and insurance premiums in Canada and dissatisfaction with wait times for public care in the UK. Fundraising for experimental and approved but inaccessible therapies was the purpose of approximately 50% of campaigns in Canada and the UK, highlighting one of the perceived shortcomings of publicly funded health care—insufficient or delayed access to novel and experimental treatments.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32143</offset><text>For patients with cancer, financial hardship is common as novel expensive therapies become the standard of care and survival rates rise. Of the 9.5 million people diagnosed with cancer between 2000 and 2012 in the US, 42.4% had exhausted their life’s financial assets within 2 years. The enormous scope of unmet financial need in cancer care is reflected in the marked overrepresentation of cancer campaigns on crowdfunding platforms. In our cohort, cancer accounted for 54.6% across the 3 countries. Notably, raising funds for alternative therapies was far more common in cancer campaigns primarily funding treatment than for the other diagnoses examined. Patients may seek alternative therapies for cancer to complement or replace proven treatments either by choice or because they were not available or failed. The popularity of campaigns for alternative therapies for cancer potentially propagates unproven and potentially dangerous therapies yielding wasted resources, false hopes, delay of appropriate palliative care, and reduced survival.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>33192</offset><text>Factors Associated With Crowdfunding Success</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>33237</offset><text>Beneficiary demographic characteristics, treatment type, the campaigning country, number of donors, fundraising goal, and campaign narrative length were important factors associated with funding success. Initial regression analysis did not demonstrate a fundraising association with Facebook shares, but further sensitivity analysis that excluded donor numbers from the model, showed an association between Facebook shares and funds raised, reflecting collinearity between Facebook shares and donor numbers. Previous crowdfunding research has shown that demographic characteristics, donor numbers, fundraising goal, campaign narrative length, and social media presence are associated with crowdfunding success. Setting a higher goal for medical campaigns may indirectly communicate depth of need to donors and promote the concept of deservingness. Campaign narrative length reflects the importance of the illness narrative to funding success. On the basis of previous research, we hypothesize that positive language in the narrative confers a fundraising advantage, whereas references to the systemic injustices that led to a given MCF campaign are infrequently observed.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>34409</offset><text>Limitations</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>34421</offset><text>This study has several limitations. First, although our data set is larger than those in previous MCF research, it is only a small subset of popular MCF campaigns. Only campaigns visible on the Discover page of GoFundMe were included in our sample, which might have led to a bias toward more successful campaigns. We adopted this approach because it allowed us to filter out dummy or unverifiable campaigns that would have made our analysis unreliable. Further work is needed to explore trends in all campaigns and other factors affecting funding success. Generalizability of our findings is limited by the use of only 1 MCF platform. It is difficult to truly ascertain the representation of MCF platforms because of a paucity of historical data and inaccessibility of proprietary information in a commercial market. Second, the veracity of the online data cannot be ensured, which restricts interpretability, but also highlights the potentially important problems of misinformation, pseudoscience, and fraud in MCF. The lack of regulation and oversight raises questions about legal and medical responsibility. Third, there are inherent limitations in manual review, especially for demographic data using only media and textual context. However, in the absence of auditable information, we believe this method provides an adequate granular view of the campaign information and demographic characteristics in MCF. Near-perfect concordance between reviewers also shows the reliability of the coded data. Moreover, we believe our approach parallels the online crowdfunding experience of a potential donor who would rely on his or her perception of a beneficiary’s identity and attribute merit based on the illness narrative and media alone.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>36161</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>36173</offset><text>We provide a foundational descriptive analysis of MCF and factors associated with success in Canada, the UK, and the US, and highlight important differences in MCF trends between publicly and privately funded health care systems. Our findings also suggest that there are racial and gender disparities in the use and success of MCF. MCF directly (through platforms that promote the victim narrative) and indirectly (by rewarding these narratives with funding success) promotes the myth that gaps in health care funding are due to misfortune and exceptionality, rather than systemic failures. As such, MCF may entrench the systemic failures that led to its need. Thus, although crowdfunding has the potential to provide short-term relief from medical financial burden for a subset of patients, it may carry wider-reaching paradoxical societal effect for those most socially disadvantaged. Further research is needed to understand the social, ethical, and economic implications of MCF within each health care setting and inform policy changes that promote equitable and accessible health care through this practice.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>37286</offset><text>References</text></passage><passage><infon key="name_0">surname:McClanahan;given-names:C</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2018</infon><offset>37297</offset></passage><passage><infon key="name_0">surname:Heller;given-names:N</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>37298</offset></passage><passage><infon key="name_0">surname:Woolley;given-names:S</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2017</infon><offset>37299</offset></passage><passage><infon key="fpage">233</infon><infon key="lpage">242</infon><infon key="name_0">surname:Berliner;given-names:LS</infon><infon key="name_1">surname:Kenworthy;given-names:NJ</infon><infon key="pub-id_doi">10.1016/j.socscimed.2017.02.008</infon><infon key="pub-id_pmid">28274601</infon><infon key="section_type">REF</infon><infon key="source">Soc Sci Med</infon><infon key="type">ref</infon><infon key="volume">187</infon><infon key="year">2017</infon><offset>37300</offset><text>Producing a worthy illness: Personal crowdfunding amidst financial crisis</text></passage><passage><infon key="name_0">surname:Jopson;given-names:B</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2018</infon><offset>37374</offset></passage><passage><infon key="fpage">1290</infon><infon key="issue">4</infon><infon key="lpage">1310</infon><infon key="name_0">surname:Bassani;given-names:G</infon><infon key="name_1">surname:Marinelli;given-names:N</infon><infon key="name_2">surname:Vismara;given-names:S.</infon><infon key="pub-id_doi">10.1007/s10961-018-9663-7</infon><infon key="section_type">REF</infon><infon key="source">J Technol Transf</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2019</infon><offset>37375</offset><text>Crowdfunding in healthcare</text></passage><passage><infon key="fpage">404</infon><infon key="issue">3</infon><infon key="lpage">424</infon><infon key="name_0">surname:Lukk;given-names:M</infon><infon key="name_1">surname:Schneiderhan;given-names:E</infon><infon key="name_2">surname:Soares;given-names:J.</infon><infon key="pub-id_doi">10.1111/cars.12210</infon><infon key="pub-id_pmid">29984886</infon><infon key="section_type">REF</infon><infon key="source">Can Rev Sociol</infon><infon key="type">ref</infon><infon key="volume">55</infon><infon key="year">2018</infon><offset>37402</offset><text>Worthy? crowdfunding the Canadian health care and education sectors: health care and education crowdfunding</text></passage><passage><infon key="fpage">E123</infon><infon key="issue">2</infon><infon key="lpage">E124</infon><infon key="name_0">surname:Sisler;given-names:J</infon><infon key="pub-id_doi">10.1503/cmaj.109-4084</infon><infon key="pub-id_pmid">22231688</infon><infon key="section_type">REF</infon><infon key="source">CMAJ</infon><infon key="type">ref</infon><infon key="volume">184</infon><infon key="year">2012</infon><offset>37510</offset><text>Crowdfunding for medical expenses</text></passage><passage><infon key="elocation-id">e026365</infon><infon key="issue">6</infon><infon key="name_0">surname:van Duynhoven;given-names:A</infon><infon key="name_1">surname:Lee;given-names:A</infon><infon key="name_2">surname:Michel;given-names:R</infon><infon key="pub-id_doi">10.1136/bmjopen-2018-026365</infon><infon key="pub-id_pmid">31227531</infon><infon key="section_type">REF</infon><infon key="source">BMJ Open</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2019</infon><offset>37544</offset><text>Spatially exploring the intersection of socioeconomic status and Canadian cancer-related medical crowdfunding campaigns</text></passage><passage><infon key="fpage">269</infon><infon key="issue">3</infon><infon key="pub-id_doi">10.1016/S1470-2045(17)30117-1</infon><infon key="pub-id_pmid">28271857</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2017</infon><offset>37664</offset><text>Mind the gap: charity and crowdfunding in health care</text></passage><passage><infon key="elocation-id">e13267</infon><infon key="issue">6</infon><infon key="name_0">surname:Durand;given-names:WM</infon><infon key="name_1">surname:Peters;given-names:JL</infon><infon key="name_2">surname:Eltorai;given-names:AEM</infon><infon key="name_3">surname:Kalagara;given-names:S</infon><infon key="name_4">surname:Osband;given-names:AJ</infon><infon key="name_5">surname:Daniels;given-names:AH</infon><infon key="pub-id_doi">10.1111/ctr.13267</infon><infon key="pub-id_pmid">29683220</infon><infon key="section_type">REF</infon><infon key="source">Clin Transplant</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2018</infon><offset>37718</offset><text>Medical crowdfunding for organ transplantation</text></passage><passage><infon key="fpage">e58</infon><infon key="issue">1</infon><infon key="lpage">e63</infon><infon key="name_0">surname:Durand;given-names:WM</infon><infon key="name_1">surname:Johnson;given-names:JR</infon><infon key="name_2">surname:Eltorai;given-names:AEM</infon><infon key="name_3">surname:Daniels;given-names:AH</infon><infon key="pub-id_doi">10.3928/01477447-20171114-04</infon><infon key="pub-id_pmid">29156070</infon><infon key="section_type">REF</infon><infon key="source">Orthopedics</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2018</infon><offset>37765</offset><text>Medical crowdfunding for patients undergoing orthopedic surgery</text></passage><passage><infon key="fpage">28</infon><infon key="issue">1</infon><infon key="lpage">29</infon><infon key="name_0">surname:Snyder;given-names:J</infon><infon key="name_1">surname:Caulfield;given-names:T</infon><infon key="pub-id_doi">10.1016/S1470-2045(18)30950-1</infon><infon key="pub-id_pmid">30614463</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2019</infon><offset>37829</offset><text>Patients’ crowdfunding campaigns for alternative cancer treatments</text></passage><passage><infon key="fpage">1717</infon><infon key="issue">12</infon><infon key="lpage">1720</infon><infon key="name_0">surname:Cohen;given-names:AJ</infon><infon key="name_1">surname:Brody;given-names:H</infon><infon key="name_2">surname:Patino;given-names:G</infon><infon key="pub-id_doi">10.1001/jamainternmed.2019.3330</infon><infon key="pub-id_pmid">31498408</infon><infon key="section_type">REF</infon><infon key="source">JAMA Intern Med</infon><infon key="type">ref</infon><infon key="volume">179</infon><infon key="year">2019</infon><offset>37898</offset><text>Use of an online crowdfunding platform for unmet financial obligations in cancer care</text></passage><passage><infon key="name_0">surname:Kale;given-names:S</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>37984</offset></passage><passage><infon key="fpage">k3829</infon><infon key="name_0">surname:Newman;given-names:M</infon><infon key="pub-id_doi">10.1136/bmj.k3829</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">362</infon><infon key="year">2018</infon><offset>37985</offset><text>Is cancer fundraising fuelling quackery?</text></passage><passage><infon key="fpage">1705</infon><infon key="issue">16</infon><infon key="lpage">1706</infon><infon key="name_0">surname:Vox;given-names:F</infon><infon key="name_1">surname:Folkers;given-names:KM</infon><infon key="name_2">surname:Turi;given-names:A</infon><infon key="name_3">surname:Caplan;given-names:AL</infon><infon key="pub-id_doi">10.1001/jama.2018.10264</infon><infon key="pub-id_pmid">30357284</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">320</infon><infon key="year">2018</infon><offset>38026</offset><text>Medical crowdfunding for scientifically unsupported or potentially dangerous treatments</text></passage><passage><infon key="fpage">1935</infon><infon key="issue">18</infon><infon key="lpage">1936</infon><infon key="name_0">surname:Snyder;given-names:J</infon><infon key="name_1">surname:Turner;given-names:L</infon><infon key="name_2">surname:Crooks;given-names:VA</infon><infon key="pub-id_doi">10.1001/jama.2018.3057</infon><infon key="pub-id_pmid">29801003</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">319</infon><infon key="year">2018</infon><offset>38114</offset><text>Crowdfunding for unproven stem cell-based interventions</text></passage><passage><infon key="fpage">1623</infon><infon key="issue">16</infon><infon key="lpage">1624</infon><infon key="name_0">surname:Young;given-names:MJ</infon><infon key="name_1">surname:Scheinberg;given-names:E</infon><infon key="pub-id_doi">10.1001/jama.2017.3078</infon><infon key="pub-id_pmid">28334321</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">317</infon><infon key="year">2017</infon><offset>38170</offset><text>The rise of crowdfunding for medical care: promises and perils</text></passage><passage><infon key="name_0">surname:Harris;given-names:A</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2018</infon><offset>38233</offset></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>38234</offset><text> Accessed December 23, 2019. https://www.crummy.com/software/BeautifulSoup/bs4/</text></passage><passage><infon key="fpage">344</infon><infon key="issue">4</infon><infon key="lpage">349</infon><infon key="name_0">surname:von Elm;given-names:E</infon><infon key="name_1">surname:Altman;given-names:DG</infon><infon key="name_2">surname:Egger;given-names:M</infon><infon key="name_3">surname:Pocock;given-names:SJ</infon><infon key="name_4">surname:Gøtzsche;given-names:PC</infon><infon key="name_5">surname:Vandenbroucke;given-names:JP</infon><infon key="pub-id_doi">10.1016/j.jclinepi.2007.11.008</infon><infon key="pub-id_pmid">18313558</infon><infon key="section_type">REF</infon><infon key="source">J Clin Epidemiol</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2008</infon><offset>38314</offset><text>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</text></passage><passage><infon key="fpage">159</infon><infon key="issue">1</infon><infon key="lpage">174</infon><infon key="name_0">surname:Landis;given-names:JR</infon><infon key="name_1">surname:Koch;given-names:GG</infon><infon key="pub-id_doi">10.2307/2529310</infon><infon key="pub-id_pmid">843571</infon><infon key="section_type">REF</infon><infon key="source">Biometrics</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">1977</infon><offset>38454</offset><text>The measurement of observer agreement for categorical data</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2017</infon><offset>38513</offset></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>38514</offset></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>38515</offset></passage><passage><infon key="name_0">surname:Monroe;given-names:R</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>38516</offset></passage><passage><infon key="elocation-id">e0229760</infon><infon key="issue">3</infon><infon key="name_0">surname:Kenworthy;given-names:N</infon><infon key="name_1">surname:Dong;given-names:Z</infon><infon key="name_2">surname:Montgomery;given-names:A</infon><infon key="name_3">surname:Fuller;given-names:E</infon><infon key="name_4">surname:Berliner;given-names:L.</infon><infon key="pub-id_doi">10.1371/journal.pone.0229760</infon><infon key="pub-id_pmid">32134984</infon><infon key="section_type">REF</infon><infon key="source">PLoS ONE</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2020</infon><offset>38517</offset><text>A cross-sectional study of social inequities in medical crowdfunding campaigns in the United States</text></passage><passage><infon key="fpage">2498</infon><infon key="issue">12</infon><infon key="lpage">2504</infon><infon key="name_0">surname:Kubota;given-names:JT</infon><infon key="name_1">surname:Li;given-names:J</infon><infon key="name_2">surname:Bar-David;given-names:E</infon><infon key="name_3">surname:Banaji;given-names:MR</infon><infon key="name_4">surname:Phelps;given-names:EA</infon><infon key="pub-id_doi">10.1177/0956797613496435</infon><infon key="pub-id_pmid">24121413</infon><infon key="section_type">REF</infon><infon key="source">Psychol Sci</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2013</infon><offset>38617</offset><text>The price of racial bias: intergroup negotiations in the ultimatum game</text></passage><passage><infon key="fpage">27</infon><infon key="lpage">30</infon><infon key="name_0">surname:Snyder;given-names:J</infon><infon key="name_1">surname:Mathers;given-names:A</infon><infon key="name_2">surname:Crooks;given-names:VA</infon><infon key="pub-id_doi">10.1016/j.socscimed.2016.09.024</infon><infon key="pub-id_pmid">27665200</infon><infon key="section_type">REF</infon><infon key="source">Soc Sci Med</infon><infon key="type">ref</infon><infon key="volume">169</infon><infon key="year">2016</infon><offset>38689</offset><text>Fund my treatment! a call for ethics-focused social science research into the use of crowdfunding for medical care</text></passage><passage><infon key="fpage">36</infon><infon key="issue">6</infon><infon key="lpage">42</infon><infon key="name_0">surname:Snyder;given-names:J</infon><infon key="pub-id_doi">10.1002/hast.645</infon><infon key="pub-id_pmid">27875643</infon><infon key="section_type">REF</infon><infon key="source">Hastings Cent Rep</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">2016</infon><offset>38804</offset><text>Crowdfunding for medical care: ethical issues in an emerging health care funding practice</text></passage><passage><infon key="name_0">surname:Cohen;given-names:RA</infon><infon key="name_1">surname:Terlizzi;given-names:E</infon><infon key="name_2">surname:Martinez;given-names:M</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>38894</offset></passage><passage><infon key="name_0">surname:Collins;given-names:SR</infon><infon key="name_1">surname:Bhupal;given-names:HK</infon><infon key="name_2">surname:Doty;given-names:MM</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>38895</offset></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>38896</offset></passage><passage><infon key="fpage">371</infon><infon key="issue">1</infon><infon key="name_0">surname:Rice;given-names:T</infon><infon key="name_1">surname:Quentin;given-names:W</infon><infon key="name_2">surname:Anell;given-names:A</infon><infon key="pub-id_doi">10.1186/s12913-018-3185-8</infon><infon key="pub-id_pmid">29776404</infon><infon key="section_type">REF</infon><infon key="source">BMC Health Serv Res</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2018</infon><offset>38897</offset><text>Revisiting out-of-pocket requirements: trends in spending, financial access barriers, and policy in ten high-income countries</text></passage><passage><infon key="elocation-id">djw205</infon><infon key="issue">2</infon><infon key="name_0">surname:Altice;given-names:CK</infon><infon key="name_1">surname:Banegas;given-names:MP</infon><infon key="name_2">surname:Tucker-Seeley;given-names:RD</infon><infon key="name_3">surname:Yabroff;given-names:KR</infon><infon key="pub-id_doi">10.1093/jnci/djw205</infon><infon key="pub-id_pmid">27754926</infon><infon key="section_type">REF</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="year">2016</infon><offset>39023</offset><text>Financial hardships experienced by cancer survivors: a systematic review</text></passage><passage><infon key="fpage">31</infon><infon key="issue">2</infon><infon key="lpage">39</infon><infon key="name_0">surname:Aggarwal;given-names:A</infon><infon key="name_1">surname:Sullivan;given-names:R</infon><infon key="pub-id_doi">10.1016/j.jcpo.2013.11.001</infon><infon key="section_type">REF</infon><infon key="source">Journal of Cancer Policy.</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2014</infon><offset>39096</offset><text>Affordability of cancer care in the United Kingdom: is it time to introduce user charges?</text></passage><passage><infon key="fpage">94</infon><infon key="issue">2</infon><infon key="lpage">97</infon><infon key="name_0">surname:Sam;given-names:D</infon><infon key="name_1">surname:Cheung;given-names:WY</infon><infon key="pub-id_doi">10.3747/co.26.4399</infon><infon key="pub-id_pmid">31043809</infon><infon key="section_type">REF</infon><infon key="source">Curr Oncol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2019</infon><offset>39186</offset><text>A population-level comparison of cancer-related and non-cancer-related health care costs using publicly available provincial administrative data</text></passage><passage><infon key="fpage">1187</infon><infon key="issue">10</infon><infon key="lpage">1199.e5</infon><infon key="name_0">surname:Gilligan;given-names:AM</infon><infon key="name_1">surname:Alberts;given-names:DS</infon><infon key="name_2">surname:Roe;given-names:DJ</infon><infon key="name_3">surname:Skrepnek;given-names:GH</infon><infon key="pub-id_doi">10.1016/j.amjmed.2018.05.020</infon><infon key="pub-id_pmid">29906429</infon><infon key="section_type">REF</infon><infon key="source">Am J Med</infon><infon key="type">ref</infon><infon key="volume">131</infon><infon key="year">2018</infon><offset>39331</offset><text>Death or debt? national estimates of financial toxicity in persons with newly-diagnosed cancer</text></passage><passage><infon key="fpage">115</infon><infon key="lpage">124</infon><infon key="name_0">surname:Cordova;given-names:A</infon><infon key="name_1">surname:Dolci;given-names:J</infon><infon key="name_2">surname:Gianfrate;given-names:G.</infon><infon key="pub-id_doi">10.1016/j.sbspro.2015.04.872</infon><infon key="section_type">REF</infon><infon key="source">Proc Soc Behav Sci</infon><infon key="type">ref</infon><infon key="volume">181</infon><infon key="year">2015</infon><offset>39426</offset><text>The determinants of crowdfunding success: evidence from technology projects</text></passage><passage><infon key="fpage">259</infon><infon key="issue">2</infon><infon key="lpage">274</infon><infon key="name_0">surname:Zhou;given-names:MJ</infon><infon key="name_1">surname:Lu;given-names:B</infon><infon key="name_2">surname:Fan;given-names:WP</infon><infon key="name_3">surname:Wang;given-names:GA</infon><infon key="pub-id_doi">10.1007/s10796-016-9723-1</infon><infon key="pub-id_pmid">29755287</infon><infon key="section_type">REF</infon><infon key="source">Inf Syst Front</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2018</infon><offset>39502</offset><text>Project description and crowdfunding success: an exploratory study</text></passage><passage><infon key="fpage">364</infon><infon key="issue">6</infon><infon key="lpage">367</infon><infon key="name_0">surname:Snyder;given-names:J</infon><infon key="name_1">surname:Crooks;given-names:VA</infon><infon key="name_2">surname:Mathers;given-names:A</infon><infon key="name_3">surname:Chow-White;given-names:P</infon><infon key="pub-id_doi">10.1136/medethics-2016-103933</infon><infon key="pub-id_pmid">28137998</infon><infon key="section_type">REF</infon><infon key="source">J Med Ethics</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">2017</infon><offset>39569</offset><text>Appealing to the crowd: ethical justifications in Canadian medical crowdfunding campaigns</text></passage></document></collection>
